Citadel Advisors
AVIR icon

Citadel Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

Citadel Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,400
Closed -$91.1K – 12642
2025
Q3 		$91.1K Buy
+31,400
New +$107K ﹤0.01% 11898
2025
Q2 		– Sell
-400
Closed -$1.2K – 12493
2025
Q1 		$1.2K Sell
400
-4,300
-91% -$13.4K ﹤0.01% 14159
2024
Q4 		$15.7K Sell
4,700
-24,300
-84% -$80.8K ﹤0.01% 13336
2024
Q3 		$97.2K Sell
29,000
-109,900
-79% -$398K ﹤0.01% 11148
2024
Q2 		$460K Buy
138,900
+6,400
+5% +$23.9K ﹤0.01% 8224
2024
Q1 		$535K Buy
132,500
+129,700
+4,632% +$508K ﹤0.01% 8243
2023
Q4 		$8.54K Sell
2,800
-100
-3% -$303 ﹤0.01% 13217
2023
Q3 		$8.7K Sell
2,900
-3,000
-51% -$10.2K ﹤0.01% 13168
2023
Q2 		$22.1K Sell
5,900
-5,600
-49% -$21K ﹤0.01% 12641
2023
Q1 		$38.5K Sell
11,500
-1,500
-12% -$6.08K ﹤0.01% 12471
2022
Q4 		$62.5K Buy
+13,000
New +$65.8K ﹤0.01% 11862
2022
Q3 		– Sell
-27,000
Closed -$192K – 12579
2022
Q2 		$192K Sell
27,000
-148,200
-85% -$1.01M ﹤0.01% 10739
2022
Q1 		$1.26M Sell
175,200
-213,200
-55% -$1.45M ﹤0.01% 7157
2021
Q4 		$3.47M Buy
388,400
+242,800
+167% +$3.78M ﹤0.01% 5048
2021
Q3 		$5.11M Buy
145,600
+29,300
+25% +$813K ﹤0.01% 4259
2021
Q2 		$2.5M Buy
116,300
+105,600
+987% +$3.17M ﹤0.01% 6047
2021
Q1 		$661K Buy
+10,700
New +$723K ﹤0.01% 9072

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors's AVIR Position: Q1 2026 in Review

Citadel Advisors increased its Atea Pharmaceuticals (AVIR) stake by 13% in Q1 2026, buying an estimated $26.2K and bringing the position to 48,401 shares worth $260K. The position accounts for ﹤0.01% of the portfolio, ranked #10798.

Citadel Advisors first reported a position in AVIR in Q4 2020 and has held it in 21 quarters since. The position peaked at $14.9M in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Citadel Advisors held 48,401 shares of Atea Pharmaceuticals worth $260K as of Q1 2026.
  • Citadel Advisors bought 5,710 Atea Pharmaceuticals shares in Q1 2026, an estimated $26.2K.
  • Atea Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10798 holding.
  • Citadel Advisors first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 21 quarters since.
  • Citadel Advisors's Atea Pharmaceuticals position peaked at $14.9M in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.